Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).

Industry: Biological Products, (No Diagnostic Substances) Peers: Aprea Therapeutics Inc Aridis Pharmaceuticals, Inc. Axim Biotechnologies Inc BIOCEPT INC Calithera Biosciences, Inc. Soleno Therapeutics Inc Gyre Therapeutics Inc Innovation Pharmaceuticals Inc.